To evaluate panitumumab plus modified fluorouracil , leucovorin , and oxaliplatin ( mFOLFOX6 ) or bevacizumab plus mFOLFOX6 in patients with previously untreated wild-type ( WT ) KRAS exon 2 ( codons 12 and 13 ) metastatic colorectal cancer ( mCRC ) .